Literature DB >> 21484169

[Psychopharmacology of autism spectrum disorders].

L Poustka1, T Banaschewski, F Poustka.   

Abstract

Autism spectrum disorders (ASD) are persistent, heterogeneous conditions that display many comorbid problems. Especially maladaptive behaviours like increased irritability, aggression, impulsivity and self-injurious behaviours are perceived as enormously stressful and can interfere with interventions targeting social and communication deficits. Medication treatments focussing on troubling comorbid problems in ASD can be fundamentally ameliorative, although core features of the disorder itself cannot be sufficiently treated. While atypical antipsychotics and stimulant medication have been proven to be effective in large multisite networks of ASD, serotonin reuptake inhibitors are of limited efficacy. Novel pharmacotherapies to improve social impairment are in the early stages of research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484169     DOI: 10.1007/s00115-010-3238-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  52 in total

1.  Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders.

Authors:  Eric Hollander; Sherie Novotny; Margaret Hanratty; Rona Yaffe; Concetta M DeCaria; Bonnie R Aronowitz; Serge Mosovich
Journal:  Neuropsychopharmacology       Date:  2003-01       Impact factor: 7.853

Review 2.  Autism and oxytocin: new developments in translational approaches to therapeutics.

Authors:  Joshua J Green; Eric Hollander
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  An update on pharmacologic treatments for autism spectrum disorders.

Authors:  Bryan H King; Jeff Q Bostic
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2006-01

4.  Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.

Authors:  P J Santosh; G Baird; N Pityaratstian; E Tavare; P Gringras
Journal:  Child Care Health Dev       Date:  2006-09       Impact factor: 2.508

5.  A pilot study of D-cycloserine in subjects with autistic disorder.

Authors:  David J Posey; Deborah L Kem; Naomi B Swiezy; Thayne L Sweeten; Ryan E Wiegand; Christopher J McDougle
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

6.  Comorbid psychiatric disorders in children with autism: interview development and rates of disorders.

Authors:  Ovsanna T Leyfer; Susan E Folstein; Susan Bacalman; Naomi O Davis; Elena Dinh; Jubel Morgan; Helen Tager-Flusberg; Janet E Lainhart
Journal:  J Autism Dev Disord       Date:  2006-10

7.  Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

Authors:  Adam J Guastella; Stewart L Einfeld; Kylie M Gray; Nicole J Rinehart; Bruce J Tonge; Timothy J Lambert; Ian B Hickie
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

8.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.

Authors:  Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

9.  Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.

Authors:  L Eugene Arnold; Benedetto Vitiello; Christopher McDougle; Larry Scahill; Bhavik Shah; Nilda M Gonzalez; Shirley Chuang; Mark Davies; Jill Hollway; Michael G Aman; Pegeen Cronin; Kathleen Koenig; Arlene E Kohn; Donald J McMahon; Elaine Tierney
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

10.  A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder.

Authors:  Stephen Bent; Kiah Bertoglio; Paul Ashwood; Alan Bostrom; Robert L Hendren
Journal:  J Autism Dev Disord       Date:  2011-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.